SPARK Neuro develops the SPARK Scan, an A.I.-driven device that utilizes EEG for neurological assessment, specifically focusing on dementia screening. The technology aims to improve diagnostic accuracy and minimize false positives.

SPARK Neuro

SPARK Neuro | 2,511 followers on LinkedIn. 40% of dementia is not diagnosed. We partner with healthcare providers and payers to change that. | SPARK Neuro&#39;s mission is to make brain health assessments a standard part of care. Targeting the 40% of dementia cases that are undiagnosed, SPARK provides a comprehensive assessment service for healthcare payers and providers, propelled by its AI-enabled and FDA-cleared EEG brain scan. 

SPARK Neuro has a history of collaborating with prestigious institutions like the Mayo Clinic and Johns Hopkins Medicine and has earned funding from the Department of Defense and the National Institutes of Health.

CEO Collective Audience CAUD: OTC, Founder, Board Member, Investor, managing partner Trajectory Ventures & Trajectory Capital

Peter Bordes

Strategy | Innovation | Ventures | Wharton MBA

Kashif Siddiqui

Finance & Accounting Executive for private and VC-backed start-up companies

Jamie Weber

President, COO at SPARK Neuro | J&J Innovation Board Fellow | Brain Health Advocate

Marinela Gombosev

SPARK Neuro is excited to announce that Harry Leider, MD, MBA has joined our team as Chief Strategy Officer. Harry Leider has over 25 years of experience serving as a senior physician executive and board member for a variety of innovative healthcare companies. Dr. Leider’s passion is leveraging his business, leadership, and clinical skills to create medical therapies, services, and intellectual property that improve the health of people struggling with chronic illnesses and conditions related to aging. Dr. Leider has served as Chief Medical Officer at numerous medical technology and care delivery companies, including Walgreens Boots Alliance, and the Medicare Advantage Plan Care Improvement Plus. He has published 25 peer-reviewed journal articles, and presented at numerous conferences and events, including at the White House on aging. He is a core faculty member and past-President of the American Association of Physician Leadership, and has been on the faculty of Harvard Medical School, the Johns Hopkins Carey School of Business, and the University of Pennsylvania School of Medicine. In his role, Dr. Leider will be instrumental in the successful launch of SPARK Neuro's dementia assessment service to risk bearing payers and provider groups. We are thrilled to have him on board!

When we share that we’re working to revolutionize dementia screening, assessment, and diagnosis, people often want to know why. Once you have dementia, isn’t that it? Why does dementia diagnosis matter? Far too many people are misinformed about the importance of dementia diagnosis. So, here at SPARK Neuro, we aim to set the record straight, and educate our stakeholders about the many reasons why dementia diagnosis matters and improves health outcomes. https://lnkd.in/eWvJ5wXV

SPARK Neuro is thrilled to announce that Richard Caselli, MD, former Chair of the Department of Neurology at Mayo Clinic, has joined our team as Medical Director. With a 35-year career at the Mayo Clinic, Dr. Caselli brings extensive expertise and leadership in neurology and cognitive aging to SPARK Neuro. He was a critical driver of the research and development that went into SPARK Scan and we are excited to continue our journey with Dr. Caselli in his new role. #brainhealth #earlydiagnosis #cognitivecare https://lnkd.in/e_JRwfNt

Metric
Company Name	SPARK Neuro
Symbol
MSH ID	COM:SPARKNEURO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	US
Stage	Series A
Employee Count
Website	sparkneuro.com
LinkedIn	spark-neuro
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital	10M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SPAR

COM:SPARKNEURO

SPARK Neuro

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue